Table 3.
OPAT ADI (n = 110)a | ||
---|---|---|
Antibiotic Management | ||
Received Pre-ED/UC PO antibiotics – n (%) | 49 (45) | |
Days of OPAT IV - median (IQR) | 3 [2] | |
Days of Post-OPAT PO – median (IQR) | 9 [3] | |
Total OPAT & Post-OPAT days – median (IQR) | 15 [4] | |
Antibiotic Regime – n (%) | ||
ED/UC prescription (IV) (n = 105) | ||
Cefazolin & metronidazoleb | 60 (57) | |
Clindamycinc | 22 [21] | |
Ceftriaxone & metronidazoleb | 13 [12] | |
Other | 10 [10] | |
OPAT prescription (IV) (n = 108) | ||
Cefazolin & metronidazoleb | 84 (78) | |
Ceftriaxone & metronidazoleb | 14 [13] | |
Clindamycinc | 10 [9] | |
OPAT discharge prescription (PO) (n = 107) | ||
Cephalexin or cefadroxil both with metronidazole | 64 (60) | |
Amoxicillin-clavulanic acid | 24 [22] | |
Clindamycinc | 16 [15] | |
Other | 3 [3] | |
Regime Specific Duration of Antibiotics – days | ||
Parenteral (IV)g | p = 0.2 | |
Narrow spectrum IV regime – mean (SD)d | 4.2 (2.2) | |
Broad spectrum IV regime – mean (SD)e | 3.2 (1.1) | |
Total course (IV & PO) (n = 107) | p = 0.4 | |
Narrow spectrum regimef – mean (SD) | 14.9 (4.3) | |
Broad spectrum regime# – mean (SD) | 15.2 (5.4) |
ED emergency department, UC urgent care, IV intravenous, PO oral route, IQR interquartile range, SD standard deviation
an = 110 unless otherwise specified
bMetronidazole component in either PO or IV formulation
cOf those receiving clindamycin 5 had clinical record of a beta-lactam allergy
dNarrow spectrum IV regime = cefazolin or penicillin both with metronidazole, PO regime = amoxicillin or cephalexin or cefadroxil with metronidazole
eBroad spectrum IV regime = clindamycin alone or ceftriaxone with metronidazole, PO regime = amoxicillin-clavulanic acid or clindamycin
fDefined as majority of days of treatment consisting of either broad or narrow spectrum agents
gExcluding cases where only a single initial dose of ceftriaxone was given and participants were then discharged on oral antibiotics